In the gastric cancer cell lines AGS and SNU-638, the PF treatment decreased cell viability and enhanced caspase-3 activity; however, with the knockdown of PERK, the PF treatment did not reduce cell viability or the increase of caspase-3 activity (Figure 5D,E). The gene discussed is CASP3; the disease is gastric cancer.